• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Tenaya Therapeutics Inc.

    4/16/26 9:11:31 AM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TNYA alert in real time by email
    DEFA14A 1 tnya-a14a-2025.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
    SECURITIES EXCHANGE ACT OF 1934

    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material Pursuant to §240.14a‑12

     

    TENAYA THERAPEUTICS, INC.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒

    No fee required

    ☐

    Fee paid previously with preliminary materials

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     


     

    img171395366_0.jpg

     

    Tenaya Therapeutics inc Your vote matters Tenaya Therapeutics, Inc. Annual Meeting of Stockholders Wednesday, May 27, 2026 8:00 AM, Pacific Time Annual Meeting to be held live via the Internet - please visit www.proxydocs.com/TNYA for more details. You must register to attend the meeting online and/or participate at www.proxydocs.com/TNYA For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting, go to www.proxydocs.com/TNYA To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 17, 2026. Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting to be held On May 27, 2026 for Stockholders of record as of April 1, 2026 To order paper materials, use one of the following methods. Internet: www.investorelections.com/TNYA Call: 1-866-648-8133 Email: paper@investorelections.com* If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. SEE REVERSE FOR FULL AGENDA Copyright © 2026 Beta NXT, Inc. or its affiliates. All Rights Reserved


     

    img171395366_1.jpg

     

    Tenaya Therapeutics, Inc. Annual Meeting of Stockholders Tenaya Therapeutics PROPOSAL 1. To elect three Class II directors to hold office until our 2029 annual meeting of stockholders and until their respective successors are elected and qualified. 1.01 Amy Burroughs, M.B.A. 1.02 Karah Parschauer, J.D. 1.03 Catherine Stehman-Breen, M.D. 2. To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026. 3. To amend and restate our 2021 Equity Incentive Plan to, among other things, increase the number of shares of our common stock reserved for issuance by approximately 3% of our outstanding shares and remove the annual limit of 4 million shares from the “evergreen” provision. NOTE: In their discretion, the Named Proxies are authorized to vote upon such other business as may properly come before the Annual Meeting or any adjustment or postponements thereof.


    Get the next $TNYA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TNYA

    DatePrice TargetRatingAnalyst
    6/10/2024Outperform
    William Blair
    11/30/2023$7.00Outperform
    Leerink Partners
    6/15/2022$25.00Buy
    H.C. Wainwright
    8/24/2021Outperform
    Cowen & Co.
    8/24/2021$31.00Overweight
    Morgan Stanley
    8/24/2021$37.00Buy
    Chardan Capital
    8/24/2021$40.00Overweight
    Piper Sandler
    More analyst ratings

    $TNYA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Column Group Iii Gp, Lp bought $24,999,999 worth of shares (35,714,284 units at $0.70) (SEC Form 4)

    4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

    3/7/25 7:14:40 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Goeddel David V bought $24,999,999 worth of shares (35,714,284 units at $0.70) (SEC Form 4)

    4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

    3/7/25 7:14:15 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Column Group Iii Gp, Lp bought $9,999,999 worth of shares (2,222,222 units at $4.50) (SEC Form 4)

    4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

    2/14/24 4:15:53 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TNYA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms

    All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCM Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom Relief and Improved Cardiac Function at Earlier Timepoint TN-201 Granted PRIME Designation by EMA; and Pediatric Indication Accepted into FDA's Rare Disease Evidence Principles Process Tenaya Management to Host a Webcast Conference Call to Review Results at 8:00 a.m. ET / 5:00 a.m. PT SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA) reported promising new interim safety and efficacy data from the company's MyPEAK™-1 Phase 1b/2 clinica

    6/3/26 7:00:00 AM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026

    SOUTH SAN FRANCISCO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it will report new interim data from Cohort 1 and Cohort 2 of the ongoing MyPEAK™-1 Phase 1b/2 trial of TN-201 gene therapy for adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Wednesday, June 3, 2026. Webcast Details: Tenaya Therapeutics will host a live webcast to review the new data from MyPEAK™-1 on Wednesday, June 3, 2026 at 8:00 a.m. ET. To access the live event, participa

    6/2/26 4:30:00 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026

    SOUTH SAN FRANCISCO, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that members of its executive team will present and participate in the upcoming Jefferies Global Healthcare Conference taking place from June 2-4, 2026, in New York, New York. Faraz Ali, Tenaya's Chief Executive Officer, will provide a company presentation on Thursday, June 4, 2026, at 3:10 p.m. ET. The live webcast of the presentation may be accessed from the Investors section of Tenaya's website. An ar

    5/29/26 8:00:00 AM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TNYA
    SEC Filings

    View All

    Tenaya Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

    8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)

    5/29/26 5:04:54 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Tenaya Therapeutics Inc.

    10-Q - Tenaya Therapeutics, Inc. (0001858848) (Filer)

    5/6/26 4:24:42 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tenaya Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)

    5/6/26 4:11:42 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TNYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Williams R Sanders

    4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

    5/29/26 7:30:09 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Walsh Jeffrey T.

    4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

    5/29/26 7:29:04 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Stehman-Breen Catherine

    4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

    5/29/26 7:28:00 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TNYA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Tenaya Therapeutics

    William Blair initiated coverage of Tenaya Therapeutics with a rating of Outperform

    6/10/24 7:25:34 AM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Leerink Partners initiated coverage on Tenaya Therapeutics with a new price target

    Leerink Partners initiated coverage of Tenaya Therapeutics with a rating of Outperform and set a new price target of $7.00

    11/30/23 7:50:26 AM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Tenaya Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Tenaya Therapeutics with a rating of Buy and set a new price target of $25.00

    6/15/22 7:41:04 AM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TNYA
    Financials

    Live finance-specific insights

    View All

    Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms

    All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCM Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom Relief and Improved Cardiac Function at Earlier Timepoint TN-201 Granted PRIME Designation by EMA; and Pediatric Indication Accepted into FDA's Rare Disease Evidence Principles Process Tenaya Management to Host a Webcast Conference Call to Review Results at 8:00 a.m. ET / 5:00 a.m. PT SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA) reported promising new interim safety and efficacy data from the company's MyPEAK™-1 Phase 1b/2 clinica

    6/3/26 7:00:00 AM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Positive Interim Data from Cohorts 1 and 2 of Tenaya's RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC

    All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count  TN-401 Gene Therapy was Well Tolerated at 3E13 vg/kg and 6E13 vg/kg Doses Post-dose Biopsies Provide Evidence of TN-401 Activity in Heart Muscle Cells PRIME Designation Granted by European Medicines Agency Tenaya Management to Host a Webcast Conference Call to Review Results on Friday, May 15 at 10:30 a.m. ET / 7:30 a.m. PT Following Late-Breaker Presentation at ASGCT 2026 SOUTH SAN FRANCISCO, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curativ

    5/15/26 6:01:00 AM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

    One-Year Cohort 1 Data and Initial Cohort 2 Data from RIDGE™-1 Phase 1b/2 Trial of TN-401 for PKP2-Associated ARVC to be Presented at ASGCT 2026 New Data from Both Cohorts of the MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM Expected in the Second Quarter 2026 Preclinical Data at MDA 2026 Highlighted TN-301's Activity in Duchenne Muscular Dystrophy Disease Models; Distinct Mechanism of HDAC6 Inhibition Supportive of TN-301's Potential in Multiple Indications Entered Research Collaboration with Alnylam to Identify and Validate Genetic Targets for Cardiovascular Conditions SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc.

    5/6/26 4:05:00 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TNYA
    Leadership Updates

    Live Leadership Updates

    View All

    Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

    Enrollment Complete in Cohorts 1 and 2 of MyPEAK™-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts Cohort 1 of RIDGE™-1 Phase 1b Trial of TN-401 Enrolled and First PKP2-associated ARVC Patient Dosed in Cohort 2 Following DSMB Recommendation to Dose Escalate and Expand Data Readouts from Both TN-201 and TN-401 Clinical Programs Planned for the Fourth Quarter of 2025 Cash Runway into Second Half of 2026 SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potent

    8/6/25 4:30:00 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

    Oxford Biomedica Appoints Leone Patterson as Non-Executive Director Oxford, UK – 26th April 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led viral vector CDMO, today announces the appointment of Ms Leone Patterson as an Independent Non-Executive Director. Ms Patterson shall join the Board on 1st May 2023. Ms Patterson has more than 20 years of public company biotech experience including in the cell and gene therapy industry and has managed significant growth within international commercial companies working across areas including strategy, finance, operations and governance. She is currently the Chief Financial and Business Officer a

    4/26/23 7:00:00 AM ET
    $NKTX
    $TNYA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors

    SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Amy Burroughs to its Board of Directors. Ms. Burroughs currently serves as President and Chief Executive Officer of Cleave Therapeutics, a clinical-stage company focused on developing novel medicines for oncology and neurodegenerative diseases. "We are pleased to welcome Ms. Burroughs to the Tenaya Board. Her substantial and diverse industry experience in the development and commercia

    12/7/22 4:30:00 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TNYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tenaya Therapeutics Inc.

    SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

    11/14/24 5:46:12 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tenaya Therapeutics Inc.

    SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

    11/14/24 1:22:39 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Tenaya Therapeutics Inc. (Amendment)

    SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

    2/14/24 5:01:36 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care